Open access · Peer reviewed · Scopus journal
Effects of glucocorticoids and tumor necrosis factor‑alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis
- 1*,
- 1,
- 1,
- 2,
- 3,
- 4,
- 4,
- 1
- 1Departments of Medical and Surgical Science, Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Catanzaro, Italy.
- 2Department of Surgery, Unit of Vascular Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy.
- 3Department of Pharmacological, Biological and Chemical Science, University of Parma, Parma, Italy.
- 4Department of Health Science, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Raffaele Serra
Departments of Medical and Surgical Science, Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Copyright: © 2014 The Author(s). This is an open access article.
Published: Jan 1, 2014, Received: Jan 13, 2014, Accepted: Feb 15, 2014
Abstract
Objective: To explore the effect of sequential treatment with glucocorticoid and tumor necrosis factor‑alpha inhibitors in patients with Takayasu arteritis (TA). Materials and Methods: In five patients with TA, the effects of the sequential treatment with prednisone for 5‑7 months and then with adalimumab (ADA) + methotrexate (MTX) or infliximab + MTX, or with ADA only, for 12 months on both clinical and laboratory findings were evaluated. Results: All treatments improved both symptoms and laboratory parameters without the development of side‑effects. Conclusions: It was hypothesized that MMP‑9 and neutrophil gelatinase‑associated lipocalin could be markers of the response to the treatments.
Keywords
Subject
Recommended articles
- Rituximab, a Safer Option for Rheumatoid Arthritis: A Comparison of the Reported Adverse Events of Approved Monoclonal Antibodies
Sweety Sharma, Somnath Basu, Ramesh K. Goyal · Journal of Pharmacology and Pharmacotherapeutics
- Severe Bone Marrow Suppression Accompanying Pulmonary Infection and Hemorrhage of the Digestive Tract Associated with Leflunomide and Low-dose Methotrexate Combination Therapy
Caihong Qu, Ying Lu, Weimin Liu · Journal of Pharmacology and Pharmacotherapeutics
- Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
V. S. Gokul Krishnan, Sharath Madhyastha, Kusugodlu Ramamoorthi · Journal of Pharmacology and Pharmacotherapeutics
- Double trouble: Cyclosporine‑induced thrombocytosis in a patient with methotrexate toxicity: Are they related?
Cherukuri Tejaswi, Saritha Mohanan, Rangaraj Murugaiyan · Journal of Pharmacology and Pharmacotherapeutics
- Metformin ameliorates methotrexate-induced hepatotoxicity
Najah R. Hadi, Fadhil G. Al-Amran, Asma Swadi · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026